Sharon A McGrath-Morrow1, Joseph M Collaco2, Barbara Detrick3, Howard M Lederman4. 1. Division of Pediatric Pulmonology, The Johns Hopkins Medical Institutions, Baltimore, MD. Electronic address: smcgrath@jhmi.edu. 2. Division of Pediatric Pulmonology, The Johns Hopkins Medical Institutions, Baltimore, MD. 3. Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD. 4. Division of Pediatric Allergy and Immunology, The Johns Hopkins Medical Institutions, Baltimore, MD.
Abstract
OBJECTIVE: To evaluate the potential link between systemic inflammation and impaired lung function in people with ataxia-telangiectasia (A-T), we hypothesized that serum levels of interleukin (IL)-6, a proinflammatory cytokine, would correlate inversely with lung function in subjects with A-T. STUDY DESIGN: Consecutive subjects with A-T were recruited from the Johns Hopkins Outpatient A-T Clinical Center. Serum levels of IL-6 and 8 were measured by enzyme-linked immunosorbent assay. Spirometry was performed in subjects ≥ 6 years of age on the same day that serum was obtained for measurements of cytokines. RESULTS: Approximately 80% of subjects had elevated serum IL-6 levels (> 1.0 pg/mL). No association was found between elevated IL-6 and age. Elevated IL-8 levels were found in 23.6% of subjects, and all subjects with elevated IL-8 levels had elevated IL-6 levels. Subjects with elevated IL-6 levels (mean: 6.14 ± 7.47 pg/mL) had significantly lower mean percent forced vital capacity (FVC%, 50.5% ± 17.8%) compared with subjects with normal serum IL-6 levels (FVC% of 66.2 ± 16.1, P = .018). Greater IL-6 levels were associated with lower FVC% even after adjustment for receiving gamma globulin therapy (P = .024) and supplemental nutrition (P = .055). CONCLUSIONS: An association was found between elevated serum IL-6 levels and lower lung function in subjects with A-T. In addition, subjects with both elevated IL-6 and IL-8 had the lowest mean lung function. These findings indicate that markers for systemic inflammation may be useful in identifying individuals with A-T at increased risk for lower lung function and may help in assessing response to therapy.
OBJECTIVE: To evaluate the potential link between systemic inflammation and impaired lung function in people with ataxia-telangiectasia (A-T), we hypothesized that serum levels of interleukin (IL)-6, a proinflammatory cytokine, would correlate inversely with lung function in subjects with A-T. STUDY DESIGN: Consecutive subjects with A-T were recruited from the Johns Hopkins OutpatientA-T Clinical Center. Serum levels of IL-6 and 8 were measured by enzyme-linked immunosorbent assay. Spirometry was performed in subjects ≥ 6 years of age on the same day that serum was obtained for measurements of cytokines. RESULTS: Approximately 80% of subjects had elevated serum IL-6 levels (> 1.0 pg/mL). No association was found between elevated IL-6 and age. Elevated IL-8 levels were found in 23.6% of subjects, and all subjects with elevated IL-8 levels had elevated IL-6 levels. Subjects with elevated IL-6 levels (mean: 6.14 ± 7.47 pg/mL) had significantly lower mean percent forced vital capacity (FVC%, 50.5% ± 17.8%) compared with subjects with normal serum IL-6 levels (FVC% of 66.2 ± 16.1, P = .018). Greater IL-6 levels were associated with lower FVC% even after adjustment for receiving gamma globulin therapy (P = .024) and supplemental nutrition (P = .055). CONCLUSIONS: An association was found between elevated serum IL-6 levels and lower lung function in subjects with A-T. In addition, subjects with both elevated IL-6 and IL-8 had the lowest mean lung function. These findings indicate that markers for systemic inflammation may be useful in identifying individuals with A-T at increased risk for lower lung function and may help in assessing response to therapy.
Authors: E R Staples; E M McDermott; A Reiman; P J Byrd; S Ritchie; A M R Taylor; E G Davies Journal: Clin Exp Immunol Date: 2008-05-26 Impact factor: 4.330
Authors: K Savitsky; A Bar-Shira; S Gilad; G Rotman; Y Ziv; L Vanagaite; D A Tagle; S Smith; T Uziel; S Sfez; M Ashkenazi; I Pecker; M Frydman; R Harnik; S R Patanjali; A Simmons; G A Clines; A Sartiel; R A Gatti; L Chessa; O Sanal; M F Lavin; N G Jaspers; A M Taylor; C F Arlett; T Miki; S M Weissman; M Lovett; F S Collins; Y Shiloh Journal: Science Date: 1995-06-23 Impact factor: 47.728
Authors: Angelo De Lauretis; Piersante Sestini; Panagiotis Pantelidis; Rachel Hoyles; David M Hansell; Nicole S L Goh; Christopher J Zappala; Dina Visca; Toby M Maher; Christopher P Denton; Voon H Ong; David J Abraham; Peter Kelleher; Laureen Hector; Athol U Wells; Elisabetta A Renzoni Journal: J Rheumatol Date: 2013-02-01 Impact factor: 4.666
Authors: Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman Journal: Orphanet J Rare Dis Date: 2016-11-25 Impact factor: 4.123
Authors: Ruth Duecker; Patrick Baer; Olaf Eickmeier; Maja Strecker; Jennifer Kurz; Alexander Schaible; Dirk Henrich; Stefan Zielen; Ralf Schubert Journal: Redox Biol Date: 2017-11-10 Impact factor: 11.799
Authors: Abrey J Yeo; Anna Henningham; Emmanuelle Fantino; Sally Galbraith; Lutz Krause; Claire E Wainwright; Peter D Sly; Martin F Lavin Journal: Sci Rep Date: 2019-02-22 Impact factor: 4.379
Authors: Sharon A McGrath-Morrow; Roland Ndeh; Joseph M Collaco; Cynthia Rothblum-Oviatt; Jennifer Wright; Michael A O'Reilly; Benjamin D Singer; Howard M Lederman Journal: PLoS One Date: 2018-12-26 Impact factor: 3.240
Authors: Patrick C Baer; Julia Sann; Ruth Pia Duecker; Evelyn Ullrich; Helmut Geiger; Peter Bader; Stefan Zielen; Ralf Schubert Journal: Cells Date: 2020-06-10 Impact factor: 6.600